117 related articles for article (PubMed ID: 10500833)
1. Lack of cross-resistance between prednisolone and methotrexate in childhood acute lymphoblastic leukemia? A preliminary analysis.
Hegge IR; Kaspers GJ; Rots MG; Jansen G; Pieters R; Veerman AJ
Adv Exp Med Biol; 1999; 457():551-5. PubMed ID: 10500833
[TBL] [Abstract][Full Text] [Related]
2. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs.
Kaspers GJ; Pieters R; Van Zantwijk CH; Van Wering ER; Van Der Does-Van Den Berg A; Veerman AJ
Blood; 1998 Jul; 92(1):259-66. PubMed ID: 9639525
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of peanut agglutinin binding in childhood acute lymphoblastic leukemia.
Kaspers GJ; Veerman AJ; Van Wering ER; Van Der Linden-Schrever BE; Van Zantwijk CH; Van Der Does-Van Den Berg A; Pieters R
Leukemia; 1996 Apr; 10(4):675-81. PubMed ID: 8618446
[TBL] [Abstract][Full Text] [Related]
4. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
Sorich MJ; Pottier N; Pei D; Yang W; Kager L; Stocco G; Cheng C; Panetta JC; Pui CH; Relling MV; Cheok MH; Evans WE
PLoS Med; 2008 Apr; 5(4):e83. PubMed ID: 18416598
[TBL] [Abstract][Full Text] [Related]
5. Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay.
Rots MG; Pieters R; Kaspers GJ; van Zantwijk CH; Noordhuis P; Mauritz R; Veerman AJ; Jansen G; Peters GJ
Blood; 1999 Feb; 93(3):1067-74. PubMed ID: 9920857
[TBL] [Abstract][Full Text] [Related]
6. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group.
Thyss A; Suciu S; Bertrand Y; Mazingue F; Robert A; Vilmer E; Mechinaud F; Benoit Y; Brock P; Ferster A; Lutz P; Boutard P; Marguerite G; Plouvier E; Michel G; Plantaz D; Munzer M; Rialland X; Chantraine JM; Norton L; Solbu G; Philippe N; Otten J
J Clin Oncol; 1997 May; 15(5):1824-30. PubMed ID: 9164191
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia.
Kaspers GJ; Veerman AJ; Popp-Snijders C; Lomecky M; Van Zantwijk CH; Swinkels LM; Van Wering ER; Pieters R
Med Pediatr Oncol; 1996 Aug; 27(2):114-21. PubMed ID: 8649318
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to methotrexate in childhood acute lymphoblastic leukemia: circumvention of thymidylate synthase inhibition.
Weigand M; Frei E; Graf N; Buchholz B; Wolfrom C; Breuer A; Wiessler M
J Cancer Res Clin Oncol; 1999; 125(8-9):513-9. PubMed ID: 10480345
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation.
Gorlick R; Cole P; Banerjee D; Longo G; Li WW; Hochhauser D; Bertino JR
Adv Exp Med Biol; 1999; 457():543-50. PubMed ID: 10500832
[TBL] [Abstract][Full Text] [Related]
11. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia.
Rots MG; Pieters R; Peters GJ; Noordhuis P; van Zantwijk CH; Kaspers GJ; Hählen K; Creutzig U; Veerman AJ; Jansen G
Blood; 1999 Mar; 93(5):1677-83. PubMed ID: 10029597
[TBL] [Abstract][Full Text] [Related]
12. A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia.
Rots MG; Pieters R; Jansen G; Kaspers GJ; Van Zantwijk CH; Noordhuis P; Voorn DA; Van Wering ER; Creutzig U; Veerman AJ; Peters GJ
Eur J Cancer; 2001 Mar; 37(4):492-8. PubMed ID: 11267859
[TBL] [Abstract][Full Text] [Related]
13. Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia.
Spenerova M; Dzubak P; Srovnal J; Radova L; Burianova R; Konecny P; Salkova S; Novak Z; Pospisilova D; Stary J; Blazek B; Hak J; Votava T; Timr P; Kaiserova E; Bubanska E; Mihal V; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Sep; 158(3):422-7. PubMed ID: 23128824
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia.
Rots MG; Pieters R; Peters GJ; Noordhuis P; Van Zantwijk CH; Henze G; Janka-Schaub GE; Veerman AJ; Jansen G
Br J Haematol; 2000 Jun; 109(3):629-34. PubMed ID: 10886214
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Peters GJ; van Woerden NL; Dubbelman B; Escherich G; Schmiegelow K; Sonneveld E; Pieters R; van de Ven PM; Jansen G; Assaraf YG; Kaspers GJ; Cloos J
J Hematol Oncol; 2015 May; 8():61. PubMed ID: 26022503
[TBL] [Abstract][Full Text] [Related]
16. The Expression and Activation of the NF-κB Pathway Correlate with Methotrexate Resistance and Cell Proliferation in Acute Lymphoblastic Leukemia.
Canevarolo RR; Cury NM; Yunes JA
Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895229
[TBL] [Abstract][Full Text] [Related]
17. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.
Kaufman Y; Drori S; Cole PD; Kamen BA; Sirota J; Ifergan I; Arush MW; Elhasid R; Sahar D; Kaspers GJ; Jansen G; Matherly LH; Rechavi G; Toren A; Assaraf YG
Cancer; 2004 Feb; 100(4):773-82. PubMed ID: 14770434
[TBL] [Abstract][Full Text] [Related]
18. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
19. Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia.
Ylinen E; Jahnukainen K; Saarinen-Pihkala UM; Jahnukainen T
Pediatr Blood Cancer; 2014 Dec; 61(12):2199-202. PubMed ID: 25174822
[TBL] [Abstract][Full Text] [Related]
20. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
